n-vinyl-2-pyrrolidinone has been researched along with Thalassemias in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Caramenti, G; Galanello, R; Modenese, A; Mosca, A; Paderi, ML; Paleari, R; Parma, R; Rocco, C; Rossini, S; Russo, V | 1 |
| Akbar, AN; de Sousa, M; Fitzgerald-Bocarsly, PA; Giardina, PJ; Grady, RW; Hilgartner, MW | 1 |
2 other study(ies) available for n-vinyl-2-pyrrolidinone and Thalassemias
| Article | Year |
|---|---|
Clinical utility of fractionating erythrocytes into "Percoll" density gradients.
Topics: Adult; Anemia, Hemolytic; Cell Fractionation; Centrifugation, Density Gradient; Child; Clinical Enzyme Tests; Drug Compounding; Erythrocyte Aging; Erythrocytes; Female; Fructose-Bisphosphate Aldolase; Glucosephosphate Dehydrogenase; Glucosephosphate Dehydrogenase Deficiency; Heterozygote; Hexokinase; Humans; Male; Phosphogluconate Dehydrogenase; Phytic Acid; Povidone; Pyruvate Kinase; Reticulocytes; Silicon Dioxide; Thalassemia | 1991 |
Decreased natural killer activity in thalassemia major: a possible consequence of iron overload.
Topics: Cell Separation; Centrifugation, Density Gradient; Cytotoxicity, Immunologic; Humans; Immunologic Deficiency Syndromes; Immunosuppressive Agents; Iron; Iron Chelating Agents; Killer Cells, Natural; Povidone; Silicon Dioxide; Thalassemia; Transfusion Reaction | 1986 |